ClinicalTrials.gg

Autism Spectrum Disorder clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,729 studies for Autism Spectrum Disorder across more than 10 countries. 503 are recruiting or about to start. 1,092 of them are mainly about Autism Spectrum Disorder (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 2 narrower conditions too, such as Autistic Disorder: 2,273 studies, 620 open.

ClinicalTrials.gov finds 2,330 studies for Autism Spectrum Disorder. How that becomes 1,728 here

This page counts the studies the registry files under Autism Spectrum Disorder, and those it files under no condition that list Autism Spectrum Disorderthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 2,330Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −538Filed under a narrower condition, counted on its own pageAutistic Disorder 530 · Asperger Syndrome 7
  3. −4List Autism Spectrum Disorder as a condition, but the registry did not file them under itMost often written as “Autism Spectrum Disorder High-Functioning” (3) and “Autism-Spectrum Disorder” (1). The registry filed them under other conditions only, most often Child Development Disorders, Pervasive (1) and Conduct Disorder (1).
  4. −60Match it another way42 name it in the title, 2 in a keyword, and 16 by a synonym or other text the search reads.
  5. 1,728The count on this page9 of them list Autism Spectrum Disorder in their own words; the registry filed them under no condition.

Status

Completed
913
Recruiting
351
Status unknown
130
Not yet recruiting
122
Active, not recruiting
81
Terminated
61

Phase

Phase 2
181
Phase 1
66
Phase 3
52
Phase 4
23
Early Phase 1
15

Where

United States
773
France
110
Italy
89
China
86
Canada
70
Taiwan
63

Who develops what

Add Autism Spectrum Disorder to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 9 programs from 8 companies, 7 with this as their studies’ main aim; 5 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Bristol-Myers Squibb and Johnson & Johnson here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
lumateperoneApproved: US 2019☆ Track3 live phase-3 studies: NCT06706674, NCT06229210, NCT06690398Johnson & Johnson
NTI164☆ Track1 live phase-3 study: NCT07257939Fenix Innovation Group
xanomelinePhase 4 trial recorded☆ Track2 live phase-3 studies: NCT07285798, NCT07284745Bristol-Myers Squibb
trospiumPhase 4 trial recorded☆ Track2 live phase-3 studies: NCT07285798, NCT07284745Bristol-Myers Squibb

The 4 in phase 3 with the nearest primary completion, of 9 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 21 Jun 2027 est.lumateperone · Johnson & Johnson · Phase 3 main aimNCT06706674 Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients — primary endpoint: Aberrant Behavior Checklist - Irritability (ABC-I) · 160 enrolled
  • 21 Jun 2027 est.lumateperone · Johnson & Johnson · Phase 3 main aimNCT06690398 Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients — primary endpoint: Aberrant Behavior Checklist - Irritability (ABC-I) · 160 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Autism Spectrum Disorder studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here SSRIs 2 open · Antipsychotics 1 open · Serotonin receptor agonists 1 open · Anxiolytics 1 open · Stimulants 1 open

Coming up

172studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger. 300 (85%) take children under 18. 1 (<1%) are for women only and 5 (1%) for men only; 92 (26%) take healthy volunteers.

Recruiting studies that take each age, of 351
AgeWomenMen
10194 (55%)197 (56%)
18161 (46%)163 (46%)
30110 (31%)111 (32%)
4090 (26%)91 (26%)
5081 (23%)81 (23%)
6568 (19%)67 (19%)
7557 (16%)57 (16%)
8553 (15%)53 (15%)

Across all 1,729 studies, recruiting or not: 86% stop at 75 or younger and 84% at 65; 85% take children; 1% are for women only and 3% for men only; 28% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Autism Spectrum Disorder studies take

Of 82 phase 2 interventional studies under Autism Spectrum Disorder, half reached primary completion within 36 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 119 mo14–27 · 35 studies——
Phase 236 mo23–52 · 82 studies—39 mo23–63 · 67 studies
Phase 333 mo25–38 · 18 studies——
Interventional, no phase25 mo12–47 · 827 studies—26 mo12–48 · 804 studies
Observational40 mo26–120 · 112 studies—47 mo27–120 · 98 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered20

Show 15 more

Studies

Recruiting first, then most recently updated. Showing 50 of 1,729. Browse all 1,729 → or search them.